SAT0186 Treatment response of intravenous tocilizumab in patients with rheumatoid arthritis based on the level of prior exposure to biologic therapy: results from the kobio. (12th June 2018)

• Record Type: Journal Article
• Authors: Shin, K.; Lee, S.-K.; Oh, S.; Kim, H.-A.; Song, Y. W.
• Is Part Of: Annals of the rheumatic diseases. Volume 77(2018)Supplement 2
• Page Start: 954
• Page End: 954
• Publication Date: 2018-06-12
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2018-eular.6111
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Previous studies have showed that response rate to biologic therapy in patients with rheumatoid arthritis (RA) are lower in those who had prior exposure to multiple biologic agents compared with first-time users. However, most of these studies targeted on patients undergoing anti-TNF therapy. Objectives: To investigate the treatment response of RA patients using intravenous tocilizumab (TOC) as the first biologic agent, comparing with those who had prior exposure to other biologic agents Methods: Data of RA patients treated with TOC were obtained from the Korean College of Rheumatology Biologics Registry (KOBIO). Patients were grouped as first (1st)-line, second (2nd)-line, and third or more (≥3rd)-line users. Clinical outcomes including SDAI changes at the first year and second year of TOC therapy were evaluated, and subsequent switching to another biologic agent and its associated factors were analyzed using the Cox proportional hazard model. Results: A total of 408 patients were included in the study; 1st-line (n = 258), 2nd -line (n = 95), ≥3rd -line (n = 55) users. The mean age was 54.0 years, and mean disease duration of 8.2 years. At baseline, mean SDAI was 30.0, and 7.1% of patients were treated without a concomitant conventional DMARD, which increased to 21.6% at the end of the second year. The clinical response of related parameters in 1st -line TOC users were more robust than the 2nd -line or ≥3rd -line users, and greater proportion of 1st -line users achieved remission or low disease activity at the second year ( p= 0.00291) (figure). In addition, switching to another agent was more frequent in the 2nd -line or ≥3rd -line users within 2 years (1st, 2nd, ≥3rd -line users, 4.7%, 15.1%, 11.1%, respectively). A multivariate analysis revealed that higher baseline SDAI (HR 1.1018, p= 0.00680) and multiple prior exposure to biologics (HR 2.5751, p= 0.0139) were predictors of subjects switching to other agents. Conclusions: Amongst RA patients with high disease activity who receive TOC, patients naïve to biologics have better treatment response and lower switch rates after two years. Reference: [1]Karlsson JA, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology2008;47:507–13. Disclosure of Interest: None declared